%0 Observational Study
%T [Results of the management of kidney cancer with extension into the inferior vena cava: A retrospective, single-center, observational study].
%A Poirier T
%A Karam G
%A Bouchot O
%A De Vergie S
%A Branchereau J
%A Perrouin-Verbe MA
%A Rigaud J
%J Prog Urol
%V 33
%N 6
%D 2023 May 17
%M 37076361
%F 1.09
%R 10.1016/j.purol.2023.03.004
%X <B>OBJECTIVE: </B>The aim of our study was to evaluate the morbidity and mortality, as well as the oncogical results of patients who had undergone surgical procedure for a kidney cancer with thrombus extension into the inferior vena cava.<BR><B>METHODS: </B>Between January 2004 and April 2020, 57 patients were operated by enlarged nephrectomy with thrombectomy for kidney cancer with thrombus extension in the inferior vena cava. Twelve patients (21%) with the use of cardiopulmonary bypass because the thrombus was upper than the sus-hepatic veins. Twenty-three patients (40.4%) were metastatic at diagnosis.<BR><B>RESULTS: </B>Perioperative mortality was 10.5%, without difference according to surgical technique. Morbidity during hospitalization was 58%, without difference according to surgical technique. Median follow-up was 40.8±40.1months. Overall survival at 2 and 5years was 60% and 28%, respectively. At 5years, the principal prognostic factor was the metastatic status at diagnosis, in multivariate analysis (OR: 0.15, P=0.03). Progression free survival mean was 28.2±40.2months. Progression free survival at 2 and 5years was 28% and 18%, respectively. All the patients who were metastatic at diagnosis had a recurrence in an average time of 5.7months (median of 3months). Thirteen percent of patients can be considered cured at the end of the study.<BR><B>CONCLUSIONS: </B>Morbidity and mortality of this surgery remain important. The metastatic status at diagnosis has appeared to be the principal prognostic factor on the survival of these patients.<BR><B>METHODS: </B>Level 4: retrospective study.